Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Sham Mailankody, Craig S. Sauter et al.|Blood Advances|2020Cited by 264
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignanciesRobert Stuver, Santosha A. Vardhana, Gunjan L. Shah et al.|Cancer Cell|2022Cited by 88
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid Qualls, Gilles Salles, Nicholas Lambert et al.|Blood|2023Cited by 47
Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective StudyDavid Qualls, Connie Lee Batlevi, Michael J. Buege et al.|Blood|2022Cited by 20
LBA1 | THE BENEFIT OF POLA‐R‐CHP IN DLBclass‐DEFINED MOLECULAR SUBSETS OF NEWLY DIAGNOSED DLBCL IN THE POLARIX TRIALEleonora Calabretta, Margaret A. Shipp, Kun Ping Lu et al.|Hematological Oncology|2025Cited by 9